Market Closed -
Nasdaq
04:00:00 2024-06-07 pm EDT
|
Pre-market
07:20:51 am
|
18.17
USD
|
-7.08%
|
|
17.92
|
-1.35%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
93.33
|
4,079
|
10,817
|
883.9
|
570.2
|
2,551
|
-
|
-
|
Enterprise Value (EV)
1 |
335.1
|
3,836
|
9,756
|
-228.1
|
169.7
|
1,714
|
1,847
|
2,551
|
P/E ratio
|
-0.72
x
|
-15.3
x
|
-6.1
x
|
-1.22
x
|
-0.89
x
|
43.1
x
|
-42.8
x
|
43.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5
x
|
8.58
x
|
9.44
x
|
0.45
x
|
0.58
x
|
2.59
x
|
4.62
x
|
4.79
x
|
EV / Revenue
|
18
x
|
8.07
x
|
8.51
x
|
-0.12
x
|
0.17
x
|
1.74
x
|
3.34
x
|
4.79
x
|
EV / EBITDA
|
-
|
-
|
-
|
0.37
x
|
-0.32
x
|
7.58
x
|
-5.4
x
|
-
|
EV / FCF
|
-2.42
x
|
-39.5
x
|
36.8
x
|
0.45
x
|
-0.22
x
|
5.94
x
|
-2.66
x
|
60.7
x
|
FCF Yield
|
-41.3%
|
-2.53%
|
2.72%
|
221%
|
-452%
|
16.8%
|
-37.5%
|
1.65%
|
Price to Book
|
-0.69
x
|
12.6
x
|
-30.9
x
|
-1.38
x
|
-0.93
x
|
-2.38
x
|
-2.51
x
|
-
|
Nbr of stocks (in thousands)
|
23,449
|
36,578
|
75,608
|
85,979
|
118,790
|
140,418
|
-
|
-
|
Reference price
2 |
3.980
|
111.5
|
143.1
|
10.28
|
4.800
|
18.17
|
18.17
|
18.17
|
Announcement Date
|
3/11/20
|
3/1/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
18.66
|
475.6
|
1,146
|
1,982
|
983.7
|
986.6
|
552.3
|
532.4
|
EBITDA
1 |
-
|
-
|
-
|
-615.7
|
-525.3
|
226.2
|
-342.4
|
-
|
EBIT
1 |
-129.6
|
-416.7
|
-1,687
|
-644.7
|
-566.5
|
124.2
|
-27.3
|
81.37
|
Operating Margin
|
-694.44%
|
-87.62%
|
-147.13%
|
-32.53%
|
-57.59%
|
12.59%
|
-4.94%
|
15.28%
|
Earnings before Tax (EBT)
1 |
-132.7
|
-418.3
|
-1,715
|
-653.6
|
-543
|
46.03
|
-41.33
|
78.23
|
Net income
1 |
-132.7
|
-418.3
|
-1,744
|
-657.9
|
-545.1
|
68.09
|
-98.46
|
63.6
|
Net margin
|
-711.04%
|
-87.94%
|
-152.12%
|
-33.2%
|
-55.41%
|
6.9%
|
-17.83%
|
11.95%
|
EPS
2 |
-5.510
|
-7.270
|
-23.44
|
-8.420
|
-5.410
|
0.4219
|
-0.4248
|
0.4167
|
Free Cash Flow
1 |
-138.5
|
-97.16
|
265.5
|
-505
|
-767.7
|
288.5
|
-693.5
|
42
|
FCF margin
|
-742.04%
|
-20.43%
|
23.16%
|
-25.48%
|
-78.05%
|
29.24%
|
-125.57%
|
7.89%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
127.53%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
423.68%
|
-
|
66.04%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/1/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
222.2
|
704
|
185.9
|
734.6
|
357.4
|
80.95
|
424.4
|
187
|
291.3
|
93.86
|
347.8
|
61.9
|
480.2
|
EBITDA
|
-
|
-
|
-
|
-118.8
|
-
|
-
|
-
|
-
|
-172.8
|
-132.7
|
-
|
-
|
-
|
EBIT
1 |
-825
|
209.3
|
-483
|
-127.2
|
-243.9
|
-312.8
|
55.46
|
-125.6
|
-183.6
|
-144.8
|
315.3
|
-142.2
|
87.93
|
Operating Margin
|
-371.27%
|
29.73%
|
-259.76%
|
-17.31%
|
-68.24%
|
-386.37%
|
13.07%
|
-67.19%
|
-63.01%
|
-154.31%
|
90.65%
|
-229.67%
|
18.31%
|
Earnings before Tax (EBT)
1 |
-829.7
|
206.1
|
-509.1
|
-166.1
|
-184.5
|
-292.7
|
57.86
|
-131.5
|
-176.7
|
-145.3
|
148.6
|
-124.7
|
155.7
|
Net income
1 |
-846.3
|
203.4
|
-510.5
|
-168.6
|
-182.2
|
-293.9
|
58.01
|
-130.8
|
-178.4
|
-147.6
|
148.4
|
-124.7
|
149.1
|
Net margin
|
-380.87%
|
28.89%
|
-274.57%
|
-22.95%
|
-50.99%
|
-363.07%
|
13.67%
|
-69.94%
|
-61.23%
|
-157.21%
|
42.68%
|
-201.52%
|
31.04%
|
EPS
2 |
-11.18
|
2.560
|
-6.530
|
-2.150
|
-2.280
|
-3.410
|
0.5800
|
-1.260
|
-1.440
|
-1.050
|
0.9821
|
-0.8521
|
0.9382
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/9/22
|
8/8/22
|
11/8/22
|
2/28/23
|
5/9/23
|
8/8/23
|
11/9/23
|
2/28/24
|
5/10/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
242
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
243
|
1,061
|
1,112
|
400
|
837
|
704
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-138
|
-97.2
|
265
|
-505
|
-768
|
289
|
-694
|
42
|
ROE (net income / shareholders' equity)
|
-
|
-190%
|
-1,266%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-74.4%
|
-47.7%
|
-83.8%
|
-27.2%
|
-26.9%
|
-9.5%
|
-22.3%
|
-
|
Assets
1 |
178.3
|
877.7
|
2,080
|
2,418
|
2,028
|
-716.8
|
441.9
|
-
|
Book Value Per Share
2 |
-5.750
|
8.840
|
-4.640
|
-7.440
|
-5.140
|
-7.630
|
-7.240
|
-
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-5.320
|
-7.090
|
-1.170
|
-1.360
|
-
|
Capex
1 |
1.86
|
220
|
57.5
|
89.1
|
53.8
|
15.9
|
5.75
|
6.1
|
Capex / Sales
|
9.95%
|
46.29%
|
5.01%
|
4.49%
|
5.47%
|
1.61%
|
1.04%
|
1.15%
|
Announcement Date
|
3/11/20
|
3/1/21
|
2/28/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
18.17
USD Average target price
21.6
USD Spread / Average Target +18.88% Consensus |
1st Jan change
|
Capi.
|
---|
| +278.54% | 2.55B | | +51.85% | 57.87B | | +41.48% | 40.25B | | -5.25% | 39.94B | | -5.16% | 28.54B | | +12.79% | 26.4B | | -20.18% | 19.33B | | +30.88% | 12.4B | | +0.61% | 12.23B | | +25.06% | 12.2B |
Other Biotechnology & Medical Research
|